본문 바로가기

RESULTS OF VITRECTOMY FOR BREAKTHROUGH VITREOUS HEMORRHAGE ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1
피인용
Web of Science 34
JCR IF
JCR 2009 2.932
ISSN
0275-004X

저자

  1. 정재호제1저자부산대학교, 부산대학교병원, 대학병원, KO
  2. 이자균부산대학교, 의과대학, 의학과, KO
  3. 이지은교신저자부산대학교, 의과대학, 의학과, 안과학교실, KO
  4. 엄부섭부산대학교, 의과대학, 의학과, KO

초록

Purpose: The purpose of this study was to evaluate the results of vitrectomy in patients with vitreous hemorrhage associated with age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). Methods: A retrospective review was conducted of consecutive cases of patients undergoing pars plana vitrectomy for nonclearing vitreous hemorrhage associated with neovascular AMD or PCV. Results: Twenty-four eyes of 23 patients were included. The mean length of time from the onset of vitreous hemorrhage to operation was 4.3 months. Twelve eyes had AMD, and 12 eyes of 11 patients had PCV. Additional treatments for active choroidal neovascularization or PCV were required in 12 eyes during follow-up. The mean visual acuity improved significantly from a logarithm of the minimum angle of resolution of 2.79 +/- 0.85 before operation to 1.61 +/- 0.98 at 2 months after operation (P < 0.001). Visual acuity was >= 20/200 in 9 eyes (37.5%) at 2 months after operation; 1 eye was in the AMD group, and the other eyes were in the PCV group. Improvement was more frequently observed in the PCV group (P = 0.005). Conclusion: In this series, the functional outcomes of vitrectomy for vitreous hemorrhage associated with AMD were inferior to outcomes of the PCV group. Vitrectomy is beneficial for improving visual function in select cases of breakthrough vitreous hemorrhage. RETINA 30: 865-873, 2010

키워드

breakthrough vitreous hemorrhagevitrectomyage-related macular degenerationpolypoidal choroidal vasculopathysubretinal hemorrhageantivascular endothelial growth factorphoto-dynamic therapyINTRAVITREAL BEVACIZUMABPHOTODYNAMIC THERAPYSECONDARYNEOVASCULARIZATIONMANAGEMENTSURGERY

식별자

WoS UID
000278549100004